Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of 5-HTR2A, DRD2,and COMT Genes Polymorphisms and Drug Plasma Concentration on Antipsychotic Response to Olanzapine in Treatment of Early-onset Schizophrenia

NCT02435654 is registered in ClinicalTrials.gov with Kunming Medical University as lead sponsor.

NCT NCT02435654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02435654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of 5-HTR2A, DRD2,and COMT Genes Polymorphisms and Drug Plasma Concentration on Antipsychotic Response to Olanzapine in Treatment of Early-onset Schizophrenia
Lead sponsor
Kunming Medical University
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2015
Completion date
December 31, 2018
Enrollment
128 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

early-onset schizophrenia